Understand the Dynamics of the Indian Pharma Sector and the Effect of Recent Changes in Patent Laws and Tax Policies on the Evolution of the Market
Research and Markets (researchandmarkets. com/reports/c32803) has announced the addition of India’s Growth Prospects in Pharma: Evolution, Not Revolution to their offering.
Dublin (PRWEB) February 15, 2006
Research and Markets (http://www. researchandmarkets. com/reports/c32803 (http://www. researchandmarkets. com/reports/c32803)) has announced the addition of India’s Growth Prospects in Pharma: Evolution, Not Revolution to their offering.
The value of the Indian pharmaceutical industry grew 11% in 2004 from 2003; with the top 10 Indian pharmas accounting for 46% of the market, and R&D spend increasing by 36%. Compliance with international intellectual property protection and an increasing threat of foreign players moving into India are factors currently changing the dynamics of the market.
This report provides an overview of the Indian healthcare system including recent legislative changes on patent laws, compulsory licensing and tax incentives. It examines the evolution of the Indian pharmaceutical industry and the performance of the 10 leading domestic players. The report contains an assessment of the strength of India’s offering in generics, contract services and innovation for domestic development and geographic expansion together with a strategic evaluation of the leading growth strategies available for Indian players and foreign companies.
Indian companies have recognized the opportunity presented by western pharma in search of lower costs and higher profits, and are exploiting the low cost base and pool of highly skilled labor in their market to develop a thriving outsourcing industry, positioning India as a key provider of contract research and manufacturing services.
India is increasing its R&D and biotechnology focus and taking advantage of the low R&D productivity of developed markets to gain partnerships with western players. These alliances enable the companies to gain expertise in discovery and development as well as maximizing revenues if and when products reach the market.
Pharmas and biotechs in the US, Europe and Japan have realized the increasing role of India at a global level. Many players are outsourcing non-core activities of the research and manufacturing process. Outsourcing is a popular option, while off-shoring via direct investment, joint venture or acquisition is also proving successful.
For more information visit http://www. researchandmarkets. com/reports/c32803 (http://www. researchandmarkets. com/reports/c32803)
Source: Datamonitor
Laura Wood
Senior Manager
Research and Markets
Press@researchandmarkets. com
Fax: +353 1 4100 980
###
